Show me Medical News
Shionogi to Present New Data at European Congress of Clinical Microbiology and Infectious Diseases 2019.pdf
Show me Medical News
Shionogi announces submission of cefiderocol Marketing Authorisation Application
Show me Medical News
Shionogi to present clinical data on lusutrombopag at the International Liver Congress™ 2019 of the European Association for the Study of the LIiver (EASL)
Show me Medical News
Shionogi announces European Union Marketing Authorisation for Rizmoic® (naldemedine)
Naldemedine meets primary endpoint in Phase 3 study for the treatment of opioid-induced constipation
Show me Medical News
13.09.2013 - Data from the FLAMINGO Phase IIIb Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare
Show me Medical News
04.09.2013 - Shionogi Launches “IRTRA® Combination Tablets LD/HD” for the Treatment of Hypertension
Show me Medical News
13.08.2013 - ViiV Healthcare Receives FDA approval for the HIV Integrase Inhibitor Tivicay® (Dolutegravir)
Show me Medical News
28.06.2013 - Shionogi Receives Manufacturing and Marketing Approval for “IRTRA® Combination Tablets LD/HD” for the Treatment of Hypertension
Show me Medical News
25.03.2013 - Shionogi Receives Marketing and Manufacturing Approval of a Drug for Lipodystrophy, "METRELEPTIN for Subcutaneous Injection 11.25 mg 'SHIONOGI'"
Show me Medical News
07.03.2013 - Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor "Dolutegravir", Disclosed by ViiV Healthcare
Show me Medical News
26.02.2013 - Shionogi receives FDA approval for Osphena (Ospemifene) for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due to menopause
Show me Medical News
18.02.2013 - U.S. Food and Drug Administration Priority Review Designation for HIV Integrase Inhibitor "Dolutegravir"
Show me Medical News
18.12.2012 - ViiV Healthcare Files a New Drug Application for the Integrase Inhibitor "Dolutegravir"
Show me Medical News
14.11.2012 - Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor "Dolutegravir", Disclosed by ViiV Healthcare
Show me Medical News
10.08.2012 - Antitrichomonal Agent, Flagyl® Approval for Additional Indication for Amoebic Dysentery, Giardiasis, Anaerobic Infection and Infectious Enteritis
Show me Medical News
10.08.2012 - Synthetic Antibacterial Agent, Baktar® Approval for Additional Indication of Prophylaxis and Treatment for Pneumocystis pneumonia
Show me Medical News
08.08.2012 - Ildong Pharmaceutical Receives a Marketing and Manufacturing Approval for Pirespa® 200mg Tablet
Show me Medical News
01.08.2012 - Shionogi Filed a New Drug Application for Recombinant Human Leptin for Lipodystrophy
Show me Medical News
30.07.2012 - Shionogi Launches "Endoxan® Powder 100mg for Oral" for Nephrotic Syndrome
Show me Medical News
30.07.2012 - Shionogi Files an Application for an Anti-hypertension Drug "S-474474", a Combination of Irbesartan and Trichlormethiazide
Show me Medical News
26.07.2012 - Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naive Adults with HIV-1
Show me Medical News
11.07.2012 - Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Show me Medical News
28.06.2012 - U. S. Food and drug administration accepts Shionogi ospemifene new drug application in vulvar and vaginal atrophy
Show me Medical News
28.05.2012 - Shionogi Launches Injectable Analgesics for Cancer Pain, "OxiFast® Injection 10mg" and "OxiFast® Injection 50mg"
Show me Medical News
26.04.2012 - Shionogi files a new drug application for ospemifene oral tablets 60mg for the treatment of vulvar and vaginal atrophy
Show me Medical News
02.04.2012 - Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV
Show me Medical News
21.03.2012 - Anticancer Agent, Ifomide®, Approval of Additional Indication of Malignant Lymphoma
Show me Medical News
21.03.2012 - Antitrichomonal Agent, Flagyl®, Approval for Additional Indication of Bacterial Vaginosis
Show me Medical News
22.02.2012 - Serotonin/Noradrenalin Reuptake Inhibitor Cymbalta® Capsule 20 mg, 30mg Approval of Additional Indication for Diabetic Neuropathic Pain
Show me Medical News
25.01.2012 - Study data show Cuvposa® reduced chronic severe drooling in patients ages 3-16 years-old with neurologic conditions.
Show me Medical News
18.01.2012 - Shionogi Receives Approval of Injectable Analgesics for Cancer Pain, "OxiFast® Injection 10mg" and "OxiFast® Injection 50mg"
Show me Medical News
29.11.2011 - Shionogi Launches Carbapenem-Type Antibiotic,"Finibax® 0.5g for Intravenous Drip Infusion"
Show me Medical News
22.04.2011 - Shionogi Receives Approval of Additional Dosage and Administration of Carbapenem Antibiotic Products: Finibax® 0.25g IV Solution and Finibax® 0.25g IV Solution Kit
Show me Medical News
07.04.2011 - Shionogi Announces Commercial Availability of CUVPOSA (glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated with Neurologic Conditions
Show me Medical News
03.02.2011 - Shionogi-ViiV Healthcare Starts Phase III Trial for "572-Trii" Fixed-Dose Combination HIV Therapy
Show me Medical News
10.01.2011 - Shionogi Inc. Announces Commercial Availability of KAPVAY (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
Show me Medical News
27.10.2010 - Shionogi Receives an Approval for an Additional Indication for Paediatric Use of RAPIACTA®, a Novel Anti-viral Drug for Influenza
Show me Medical News
21.10.2010 - Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
Show me Medical News
04.10.2010 - Shionogi announces FDA approval of kapvay - the first and only therapy approved for use with stimulant medication for the treatment of ADH
Show me Medical News
29.07.2010 - Shionogi Inc. Announces FDA approval of cuvposa for the treatment of chronic severe drooling in paediatric patients with neurologic conditions
Show me Medical News
23.07.2010 - Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference
Show me Medical News
02.03.2010 - Shionogi enters into exclusive license agreement with Quatrx Pharmaceuticals to market Ospemifene
Show me Medical News
15.02.2010 - Shionogi Files an Additional Application for Paediatric Use of “RAPIACTA®” a Novel Anti-viral Drug for Influenza
Show me Medical News
26.01.2010 - A Novel Anti-viral Drug for Influenza,“Rapiacta 300mg Bag for Intravenous Drip Infusion” and “Rapiacta 150mg Vial for Intravenous Drip Infusion” Launch